Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM CHLORIDE 10% vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM CHLORIDE 10% vs KAON CL, answered by our medical review team.
CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM CHLORIDE 10% and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM CHLORIDE 10% and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.